Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta Inc (Nasdaq: AZTA) is a global leader in life sciences solutions, providing essential tools for drug development, clinical research, and genomic discovery. This page aggregates official press releases and verified news about the company’s advancements in cold-chain sample management, automated storage systems, and multiomics services.
Investors and researchers will find timely updates on Azenta’s operational milestones, including earnings reports, strategic partnerships, product innovations, and industry recognition. The curated content addresses key areas such as sample integrity technologies, genomic data accuracy, and global service expansions.
Key updates include developments from Azenta’s core segments: Life Sciences Products (automated storage solutions, lab consumables) and Life Sciences Services (genomic sequencing, multiomics analytics). Content is organized to help stakeholders track progress in critical research areas like precision medicine and biotherapeutic development.
Bookmark this page for streamlined access to Azenta’s latest announcements, or check regularly for insights into how the company continues to shape the future of life sciences infrastructure and biomedical innovation.
Azenta (Nasdaq: AZTA) has scheduled its fiscal 2025 second quarter earnings announcement for Wednesday, May 7, 2025, before market opening. The earnings report will cover the quarter ended March 31, 2025.
The company will host a conference call and live webcast to discuss the financial results on May 7, 2025, at 8:30 a.m. Eastern Time. Investors, analysts, and media representatives can access the live webcast through Azenta's investor relations website. A replay of the event will be available starting May 8, 2025, at 8:30 a.m. ET.
Azenta (Nasdaq: AZTA) has released its 2024 Environmental, Social, & Governance (ESG) Report, outlining achievements across three main pillars: Environmental Protection, Social Impact, and Responsible Operations.
Key 2024 milestones include:
- ~20% reduction in Scope 1 & 2 Greenhouse Gas emissions compared to 2022
- Over 60% electricity sourced from renewable sources
- Launch of BioArc™ Ultra for eco-friendly sample storage
- Introduction of LGBTQIA+ Employee Resource Group (Azenta PRISM)
- Implementation of Azenta THRIVE platform with LinkedIn Learning® integration
- 100% of global buyer team trained on sustainable sourcing
- EcoVadis® partnership expansion to evaluate ESG performance of over 50% of Tier 1 suppliers by spend
Azenta (Nasdaq: AZTA) has announced its participation in the upcoming Virtual KeyBanc Capital Markets Healthcare Forum. The company's Executive Vice President and Chief Financial Officer, Lawrence Y. Lin, will deliver a presentation at the event on Wednesday, March 19, 2025, at 10:30 am ET.
Investors and interested parties can access the live webcast through the Azenta investor relations website at https://investors.azenta.com/events. A replay option will be made available after the presentation concludes.
Azenta (NASDAQ: AZTA) reported Q1 FY2025 results with revenue from continuing operations at $148 million, up 4% year-over-year. The company's performance was marked by growth in both major segments: Sample Management Solutions revenue reached $81 million (+3% YoY) and Multiomics revenue hit $66 million (+6% YoY).
The company reported a diluted EPS loss of ($0.21) from continuing operations and total diluted EPS of ($0.29). Adjusted EBITDA was $13 million with a margin of 9.0%, showing a 400 basis point improvement year-over-year. The quarter ended with $530 million in cash, cash equivalents, and marketable securities, generating free cash flow of $22 million.
For FY2025, Azenta maintains its guidance of 3-5% organic revenue growth and expects adjusted EBITDA margin expansion of approximately 300 basis points compared to FY2024.
Azenta (NASDAQ: AZTA) announced the election of Dipal Doshi to its Board of Directors at its Annual Meeting of Stockholders. Doshi, who currently serves as the Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA), brings extensive experience in the biotechnology and pharmaceutical industries.
John Marotta, President and CEO of Azenta, highlighted Doshi's exceptional leadership qualities and valuable experience in strategy, operational and commercial growth, along with his perspective as a current public company CEO. Doshi expressed enthusiasm about joining Azenta during a important period in its development, emphasizing the company's strong market leadership position and commitment to growth and innovation.
Azenta (Nasdaq: AZTA) has announced it will release its fiscal first quarter 2025 financial results on Wednesday, February 5, 2025, before market opening. The earnings report will cover the period ended December 31, 2024.
The company will host a conference call and live webcast to discuss the results on the same day at 8:30 a.m. Eastern Time. The webcast will be accessible through Azenta's investor relations website, with a replay available starting February 6, 2025, at 8:30 a.m. ET.
Azenta (Nasdaq: AZTA) has been selected by UK Biocentre to provide its BioArc Ultra automated storage system for expanding large-scale sample storage capabilities. This addition complements seven existing BioArc Flex systems at their facility. The new system will be installed at UK Biocentre's 70,000 square-foot facility in Milton Keynes, England.
The BioArc Ultra will increase the facility's storage capacity by 16 million samples, adding to its current 35 million sample capacity. The system features high-density, fully automated -80°C storage with picking capability of up to 9 million picks per year. The solution includes FluidX 2D-coded screw-cap tubes for enhanced inventory management.
Key benefits include reduced footprint, lower labor requirements, and decreased electricity costs. The system employs an eco-friendly refrigeration system with zero Ozone Depletion Potential and zero Global Warming Potential. UK Biocentre will use this technology to support the Our Future Health study, which aims to develop new ways to prevent, detect, and treat diseases across up to 5 million people in the UK.
Azenta (Nasdaq: AZTA) has announced its participation in the Stephens Annual Investment Conference on Wednesday, November 20, 2024. The company's management will deliver a presentation starting at 1:00 pm CT. Investors and interested parties can access the live webcast through Azenta's investor relations website. A replay option will be made available after the event concludes.
Azenta reported its Q4 and FY 2024 results, highlighting a 4% revenue growth in Sample Management Solutions and Multiomics. The company anticipates a 3%-5% organic revenue growth for FY 2025 and a 300 basis points EBITDA margin expansion. For Q4, revenue was $170 million, down 1% YoY, with a 2% organic decline. Sample Management Solutions and Multiomics grew by 5% and 8% organically, respectively, while B Medical Systems saw a 35% decline. FY 2024 revenue was $656 million, down 1% YoY, driven by a 27% decline in B Medical Systems revenue. The company reported an operating loss of $201 million for FY 2024, with a non-GAAP diluted EPS of $0.41. Azenta plans to sell B Medical Systems to focus on core businesses and appointed Lawrence Y. Lin as the new CFO. They ended FY 2024 with $522 million in cash and equivalents and repurchased 4.9 million shares worth $249 million in Q4.
Azenta (Nasdaq: AZTA) has scheduled its fiscal fourth quarter and full year 2024 earnings announcement for Tuesday, November 12, 2024, after market close. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day to discuss the financial results for the period ended September 30, 2024. A replay of the webcast will be available starting at 8:30 a.m. ET on November 13, 2024.
